The objective was to enroll participants with metabolic syndrome plus elevated CRP concentrations of ≥3 mg/L, indicative of a high risk for CVD, into a double-blind randomized placebo-controlled trial of a high vitamin C micronutrient supplement versus placebo control for 12 weeks duration. This evidence concerns the gene CRP and metabolic syndrome.